AU2011315831B2 - Methods for inhibiting cell proliferation in EGFR-driven cancers - Google Patents

Methods for inhibiting cell proliferation in EGFR-driven cancers Download PDF

Info

Publication number
AU2011315831B2
AU2011315831B2 AU2011315831A AU2011315831A AU2011315831B2 AU 2011315831 B2 AU2011315831 B2 AU 2011315831B2 AU 2011315831 A AU2011315831 A AU 2011315831A AU 2011315831 A AU2011315831 A AU 2011315831A AU 2011315831 B2 AU2011315831 B2 AU 2011315831B2
Authority
AU
Australia
Prior art keywords
heterocyclic ring
atoms
substituted
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011315831A
Other languages
English (en)
Other versions
AU2011315831A1 (en
Inventor
David C. Dalgarno
Juan J. Miret
Victor M. Rivera
William C. Shakespeare
Xiaotian Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2011315831A1 publication Critical patent/AU2011315831A1/en
Priority to AU2013203904A priority Critical patent/AU2013203904A1/en
Application granted granted Critical
Publication of AU2011315831B2 publication Critical patent/AU2011315831B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: ARIAD PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011315831A 2010-10-14 2011-10-14 Methods for inhibiting cell proliferation in EGFR-driven cancers Active AU2011315831B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203904A AU2013203904A1 (en) 2010-10-14 2013-04-11 Methods for inhibiting cell proliferation in EGFR-driven cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39329110P 2010-10-14 2010-10-14
US61/393,291 2010-10-14
PCT/US2011/056457 WO2012051587A1 (en) 2010-10-14 2011-10-14 Methods for inhibiting cell proliferation in egfr-driven cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203904A Division AU2013203904A1 (en) 2010-10-14 2013-04-11 Methods for inhibiting cell proliferation in EGFR-driven cancers

Publications (2)

Publication Number Publication Date
AU2011315831A1 AU2011315831A1 (en) 2013-03-28
AU2011315831B2 true AU2011315831B2 (en) 2015-01-22

Family

ID=45938740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011315831A Active AU2011315831B2 (en) 2010-10-14 2011-10-14 Methods for inhibiting cell proliferation in EGFR-driven cancers

Country Status (12)

Country Link
US (1) US20140024620A1 (https=)
EP (1) EP2627179A4 (https=)
JP (1) JP2013539795A (https=)
KR (1) KR20130139999A (https=)
CN (2) CN103153064B (https=)
AU (1) AU2011315831B2 (https=)
BR (1) BR112013008816A2 (https=)
CA (1) CA2810900A1 (https=)
EA (1) EA201390550A1 (https=)
IL (1) IL225351A0 (https=)
MX (1) MX2013004086A (https=)
WO (1) WO2012051587A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
EP2844642B8 (en) * 2012-05-05 2019-12-25 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN102977104A (zh) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 2,4-二氯-7-氢-吡咯并（2,3）嘧啶的合成
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
US10300058B2 (en) 2014-04-18 2019-05-28 Xuanzhu Pharma Co., Ltd. Tyrosine kinase inhibitor and uses thereof
US10053477B2 (en) * 2014-07-04 2018-08-21 Qilu Pharmaceutical Co., Ltd. Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
CN106699810A (zh) * 2015-11-17 2017-05-24 清华大学 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
EP3381925B1 (en) * 2015-11-27 2020-12-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
CN109071512A (zh) * 2016-02-03 2018-12-21 重庆复创医药研究有限公司 作为激酶抑制剂的含磷化合物
CN107098887B (zh) * 2016-02-22 2019-08-09 复旦大学 嘧啶类化合物
EP3453392B1 (en) 2016-05-17 2025-10-22 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired egfr-tki resistance
EP3504203B1 (en) 2016-08-29 2022-09-28 The Regents of The University of Michigan Aminopyrimidines as alk inhibitors
US11180482B2 (en) * 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
CN110520110A (zh) * 2017-03-08 2019-11-29 阿瑞雅德制药公司 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂
PH12020550034B1 (en) * 2017-07-19 2024-05-22 Chia Tai Tianqing Pharmaceutical Group Co Ltd Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
SG11202002060XA (en) * 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
JP7043098B2 (ja) * 2017-12-21 2022-03-29 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジアニリノピリミジン系化合物
CN110305161A (zh) * 2018-03-20 2019-10-08 暨南大学 2-氨基嘧啶类化合物及其应用
CN110467638A (zh) * 2018-05-09 2019-11-19 北京赛特明强医药科技有限公司 一种含有间氯苯胺类取代基的双氨基氯代嘧啶类化合物、制备方法及其应用
CN110467637B (zh) * 2018-05-09 2022-02-18 北京赛特明强医药科技有限公司 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用
CN110526941A (zh) * 2018-05-24 2019-12-03 北京赛特明强医药科技有限公司 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用
CN111836819A (zh) * 2018-05-24 2020-10-27 北京赛特明强医药科技有限公司 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
CN110835320B (zh) * 2018-08-15 2025-12-30 江苏奥赛康药业有限公司 二氨基嘧啶类化合物及其应用
JP2022517396A (ja) * 2019-01-18 2022-03-08 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN111825719A (zh) * 2019-04-15 2020-10-27 北京赛特明强医药科技有限公司 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
CN113166103B (zh) * 2019-04-26 2022-12-16 江苏先声药业有限公司 Egfr抑制剂及其应用
CN112513029B (zh) * 2019-06-21 2023-10-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
CN114430739A (zh) * 2019-07-26 2022-05-03 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
WO2021018003A1 (zh) * 2019-07-26 2021-02-04 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
CN112538072B (zh) * 2019-09-21 2024-02-06 齐鲁制药有限公司 氨基嘧啶类egfr抑制剂
CN114502564A (zh) * 2019-09-26 2022-05-13 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
CN114430741A (zh) * 2019-10-17 2022-05-03 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
AU2020385527B2 (en) * 2019-11-21 2023-04-13 Tyk Medicines, Inc. Compound used as EGFR kinase inhibitor and use thereof
CN114728932B (zh) * 2019-11-29 2024-11-29 江苏先声药业有限公司 作为egfr激酶抑制剂的多芳基化合物
WO2021160087A1 (zh) * 2020-02-14 2021-08-19 贝达药业股份有限公司 喹啉基膦氧化合物及其组合物和用途
AU2021227907A1 (en) * 2020-02-25 2022-09-29 Dana-Farber Cancer Institute, Inc. Potent and selective degraders of ALK
EP4129996A4 (en) * 2020-03-23 2023-07-12 Qilu Pharmaceutical Co., Ltd. Novel aminopyrimidine egfr inhibitor
CN111777592B (zh) * 2020-06-22 2021-06-18 温州医科大学 一种n4-(2,5-二甲氧基苯基)-嘧啶二胺类靶向ddr1抑制剂及其制备和应用
CA3196857A1 (en) * 2020-10-30 2022-05-05 Gurulingappa Hallur Pyrimidine compounds, compositions, and medicinal applications thereof
CN116710444A (zh) * 2020-10-30 2023-09-05 缆图药品公司 嘧啶化合物、组合物及其医药应用
CN116685583A (zh) * 2020-10-30 2023-09-01 缆图药品公司 嘧啶化合物、组合物及其医药应用
PE20231515A1 (es) * 2020-10-30 2023-09-28 Blueprint Medicines Corp Compuestos de pirimidina, composiciones y aplicaciones medicas de esta
WO2022127807A1 (zh) * 2020-12-18 2022-06-23 江苏豪森药业集团有限公司 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用
AU2022205713A1 (en) * 2021-01-07 2023-07-27 Ontario Institute For Cancer Research (Oicr) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
WO2022147622A1 (en) * 2021-01-07 2022-07-14 Ontario Institute For Cancer Research (Oicr) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
TW202237597A (zh) * 2021-03-19 2022-10-01 大陸商上海齊魯製藥研究中心有限公司 新型egfr降解劑
WO2022199589A1 (zh) * 2021-03-23 2022-09-29 南京明德新药研发有限公司 嘧啶衍生物
BR112023019370A2 (pt) * 2021-04-01 2023-12-26 Univ Yonsei Iacf Composto, e, composição farmacêutica para prevenir, melhorar ou tratar câncer
WO2022228556A1 (en) * 2021-04-30 2022-11-03 Beigene, Ltd. Egfr degraders and associated methods of use
WO2022227032A1 (en) * 2021-04-30 2022-11-03 Beigene (Beijing) Co., Ltd. Egfr degraders and associated methods of use
WO2023006088A1 (zh) * 2021-07-30 2023-02-02 浙江大学智能创新药物研究院 一种用于egfr激酶抑制剂的化合物、组合物及其应用
WO2024005516A1 (ko) * 2022-06-28 2024-01-04 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
CN115260234A (zh) * 2022-07-01 2022-11-01 江苏医药职业学院 一种2-氨基-4-氨基芳基磷氧基嘧啶化合物及其制备方法与应用
CN116284001B (zh) * 2023-01-30 2025-06-06 中国药科大学 Dclk1抑制剂、制备方法、药物组合物和应用
CN117187271B (zh) * 2023-03-07 2024-08-27 艾博生物科技(上海)有限公司 编码激活性EGFR突变肽的免疫调节治疗mRNA组合物
CN121319053A (zh) * 2024-07-10 2026-01-13 中国科学院基础医学与肿瘤研究所(筹) 一类带有二乙烯基磷酰基的2-氨基嘧啶类化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343782B1 (en) * 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
JP2009514876A (ja) * 2005-11-03 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼのための化合物および組成物
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008039359A2 (en) * 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
MX2010009743A (es) * 2008-03-05 2010-09-28 Novartis Ag Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
PT2585470T (pt) * 2010-06-23 2017-03-06 Hanmi Science Co Ltd Novos derivados fundidos de pirimidina para inibição da actividade da tirosina cinase
EP2635285B1 (en) * 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (ja) * 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
BR112013008816A2 (pt) 2016-06-28
EP2627179A1 (en) 2013-08-21
CN103153064B (zh) 2015-04-22
EP2627179A4 (en) 2014-04-02
US20140024620A1 (en) 2014-01-23
JP2013539795A (ja) 2013-10-28
CN104814970A (zh) 2015-08-05
EA201390550A1 (ru) 2013-08-30
AU2011315831A1 (en) 2013-03-28
WO2012051587A1 (en) 2012-04-19
CN103153064A (zh) 2013-06-12
CA2810900A1 (en) 2012-04-19
KR20130139999A (ko) 2013-12-23
MX2013004086A (es) 2013-07-05
IL225351A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AU2011315831B2 (en) Methods for inhibiting cell proliferation in EGFR-driven cancers
JP5999177B2 (ja) Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
JP6469567B2 (ja) Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) Methods for inhibiting cell proliferation in ALK-driven cancers
KR102178692B1 (ko) 암의 치료에서 유용한 6,7,8,9-테트라하이드로-3h-피라졸로[4,3-f]이소퀴놀린 유도체
KR102134204B1 (ko) 신규 화합물
JP2023523640A (ja) ベンゾチアゾリルビアリール系化合物、その調製方法及び使用
CN115551868A (zh) 大环化合物和其用途
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
CN112266384A (zh) ErbB受体抑制剂
MX2014004857A (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
HUE029418T2 (en) Ubikvitin-specific protease 7 selective and reversible inhibitors
ES2709003T3 (es) Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico
AU2013203904A1 (en) Methods for inhibiting cell proliferation in EGFR-driven cancers
EP2844642B1 (en) Compounds for inhibiting cell proliferation in egfr-driven cancers
HK40045061A (en) Erbb receptor inhibitors
EA037533B1 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
HK1033741A (en) Amide derivatives and nociceptin antagonists

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ DALGARNO, DAVID C.; SHAKESPEARE, WILLIAM C.; ZHU, XIAOTIAN; RIVERA, VICTOR M. AND MIRET, JUAN J.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): ARIAD PHARMACEUTICALS, INC.